Literature DB >> 30091231

Technical challenges and clinical relevance of single antigen bead C1q/C3d testing and IgG subclass analysis of human leukocyte antigen antibodies.

Gonca E Karahan1, Frans H J Claas1, Sebastiaan Heidt1.   

Abstract

Luminex single antigen bead assays revolutionized human leukocyte antigen (HLA) antibody detection owing to their superior sensitivity compared to conventional methods. Nevertheless, the advent of higher sensitivity came at the expense of difficulty in clinical decision-making, since not all luminex detectable antibodies are clinically relevant. Therefore, new tools such as C1q/C3d assays and IgG subclass analysis emerged with the aim to discriminate the inert antibodies from the deleterious ones. Here, we provide an overview on the technical challenges related to these different HLA antibody detection systems and briefly refer to the recent literature regarding the clinical relevance of these assays, mainly in the field of kidney transplantation.
© 2018 Steunstichting ESOT.

Entities:  

Keywords:  antibody-mediated rejection; donor-specific antibody; kidney transplantation; luminex

Mesh:

Substances:

Year:  2018        PMID: 30091231     DOI: 10.1111/tri.13327

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  2 in total

1.  Surrogate Endpoints for Late Kidney Transplantation Failure.

Authors:  Maarten Naesens; Klemens Budde; Luuk Hilbrands; Rainer Oberbauer; Maria Irene Bellini; Denis Glotz; Josep Grinyó; Uwe Heemann; Ina Jochmans; Liset Pengel; Marlies Reinders; Stefan Schneeberger; Alexandre Loupy
Journal:  Transpl Int       Date:  2022-05-20       Impact factor: 3.842

2.  Proposed Definitions of Antibody-Mediated Rejection for Use as a Clinical Trial Endpoint in Kidney Transplantation.

Authors:  Candice Roufosse; Jan Ulrich Becker; Marion Rabant; Daniel Seron; Maria Irene Bellini; Georg A Böhmig; Klemens Budde; Fritz Diekmann; Denis Glotz; Luuk Hilbrands; Alexandre Loupy; Rainer Oberbauer; Liset Pengel; Stefan Schneeberger; Maarten Naesens
Journal:  Transpl Int       Date:  2022-05-20       Impact factor: 3.842

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.